Beam Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Cash & Equivalents	444.61	245.52	572.74	177.01	50.55	Upgrade
Short-Term Investments	753.98	845.37	405.65	137.5	54.63	Upgrade
Cash & Cash Equivalents	1,199	1,091	978.39	314.51	105.18	Upgrade
Cash Growth	9.87%	11.50%	211.08%	199.02%	-28.90%	Upgrade
Receivables	0	0	300	0	0	Upgrade
Other Current Assets	12.45	2.01	-5.39	-6.19	-10.64	Upgrade
Total Current Assets	1,211	1,093	1,273	308.32	94.54	Upgrade
Property, Plant & Equipment	237.81	234.13	186.98	125.37	43.25	Upgrade
Other Long-Term Assets	10.87	14.69	14.47	17.98	18.31	Upgrade
Total Long-Term Assets	248.67	248.82	201.45	143.36	61.56	Upgrade
Total Assets	1,460	1,342	1,474	451.68	156.1	Upgrade
Accounts Payable	1.62	9.03	7.47	6.31	7.85	Upgrade
Deferred Revenue	178.59	338.15	348.57	0.42	0	Upgrade
Current Debt	12.78	10.38	9.83	6.34	5.64	Upgrade
Other Current Liabilities	12.58	-133.97	-152.44	89.27	15.65	Upgrade
Total Current Liabilities	205.57	223.6	213.44	102.34	29.14	Upgrade
Long-Term Debt	159.91	168.63	137.82	101.31	25.6	Upgrade
Other Long-Term Liabilities	112.91	216.02	296.46	2.47	0.42	Upgrade
Total Long-Term Liabilities	272.82	384.65	434.28	103.78	26.02	Upgrade
Total Liabilities	478.39	608.24	647.72	206.12	55.15	Upgrade
Total Debt	172.69	179.01	147.64	107.64	31.24	Upgrade
Debt Growth	-3.53%	21.24%	37.16%	244.59%	127.19%	Upgrade
Retained Earnings	-1,189.89	-1,057.36	-768.27	-397.64	-203.04	Upgrade
Comprehensive Income	0.6	-2.43	-0.05	-0.01	0.02	Upgrade
Shareholders' Equity	981.33	733.47	826.74	245.56	-201.1	Upgrade
Net Cash / Debt	1,026	911.88	830.75	206.87	73.94	Upgrade
Net Cash / Debt Growth	12.50%	9.77%	301.59%	179.77%	-44.90%	Upgrade
Net Cash Per Share	13.30	13.02	12.93	4.43	11.41	Upgrade
Working Capital	1,005	869.3	1,060	205.98	65.41	Upgrade
Book Value Per Share	12.72	10.48	12.87	5.25	-31.04	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).